Pharmaceutical Pricing and Reimbursement Policies in Mexico:
This paper examines aspects of the policy environment and market characteristics of Mexico's pharmaceutical sector, and assesses the degree to which Mexico has achieved certain policy goals. This paper questions the effectiveness of the maximum price regulation. It notes that retail prices for...
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Weitere Verfasser: | |
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Paris
OECD Publishing
2007
|
| Schriftenreihe: | OECD Health Working Papers
no.25 |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Zusammenfassung: | This paper examines aspects of the policy environment and market characteristics of Mexico's pharmaceutical sector, and assesses the degree to which Mexico has achieved certain policy goals. This paper questions the effectiveness of the maximum price regulation. It notes that retail prices for pharmaceuticals are relatively high, although proximity to the United States may have some influence. Although not wholly successful in containing overall drug expenditures, the federal government can claim some measure of success for the public sector market. A high reliance on out-of-pocket spending brings into question the sustainability of financing pharmaceuticals in Mexico. It also contributes to greater inequality, although a new health insurance scheme, the Seguro Popular, is addressing the latter with some success as it endeavours to provide coverage for the half of Mexico's population without health insurance. Finally, the paper acknowledges the government.s efforts in improving efficiency of expenditures and quality of care through new bioequivalency requirements for generics. However, an unintended side-effect of the loss of low cost, non-bioequivalent drugs may be higher average prices for pharmaceuticals. |
| Beschreibung: | 1 Online-Ressource (66 p.) 21 x 29.7cm. |
| DOI: | 10.1787/302355455158 |
Internformat
MARC
| LEADER | 00000cam a22000002 4500 | ||
|---|---|---|---|
| 001 | ZDB-13-SOC-06129618X | ||
| 003 | DE-627-1 | ||
| 005 | 20231204121119.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210204s2007 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1787/302355455158 |2 doi | |
| 035 | |a (DE-627-1)06129618X | ||
| 035 | |a (DE-599)KEP06129618X | ||
| 035 | |a (FR-PaOEC)302355455158 | ||
| 035 | |a (EBP)06129618X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a I11 |2 jelc | ||
| 084 | |a I18 |2 jelc | ||
| 100 | 1 | |a Moïse, Pierre |e VerfasserIn |4 aut | |
| 245 | 1 | 0 | |a Pharmaceutical Pricing and Reimbursement Policies in Mexico |c Pierre, Moïse and Elizabeth, Docteur |
| 264 | 1 | |a Paris |b OECD Publishing |c 2007 | |
| 300 | |a 1 Online-Ressource (66 p.) |c 21 x 29.7cm. | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 490 | 0 | |a OECD Health Working Papers |v no.25 | |
| 520 | |a This paper examines aspects of the policy environment and market characteristics of Mexico's pharmaceutical sector, and assesses the degree to which Mexico has achieved certain policy goals. This paper questions the effectiveness of the maximum price regulation. It notes that retail prices for pharmaceuticals are relatively high, although proximity to the United States may have some influence. Although not wholly successful in containing overall drug expenditures, the federal government can claim some measure of success for the public sector market. A high reliance on out-of-pocket spending brings into question the sustainability of financing pharmaceuticals in Mexico. It also contributes to greater inequality, although a new health insurance scheme, the Seguro Popular, is addressing the latter with some success as it endeavours to provide coverage for the half of Mexico's population without health insurance. Finally, the paper acknowledges the government.s efforts in improving efficiency of expenditures and quality of care through new bioequivalency requirements for generics. However, an unintended side-effect of the loss of low cost, non-bioequivalent drugs may be higher average prices for pharmaceuticals. | ||
| 650 | 4 | |a Social Issues/Migration/Health | |
| 650 | 4 | |a Mexico | |
| 700 | 1 | |a Docteur, Elizabeth |e MitwirkendeR |4 ctb | |
| 856 | 4 | 0 | |l FWS01 |p ZDB-13-SOC |q FWS_PDA_SOC |u https://doi.org/10.1787/302355455158 |3 Volltext |
| 912 | |a ZDB-13-SOC | ||
| 912 | |a ZDB-13-SOC | ||
| 951 | |a BO | ||
| 912 | |a ZDB-13-SOC | ||
| 049 | |a DE-863 | ||
Datensatz im Suchindex
| DE-BY-FWS_katkey | ZDB-13-SOC-06129618X |
|---|---|
| _version_ | 1816797336192417792 |
| adam_text | |
| any_adam_object | |
| author | Moïse, Pierre |
| author2 | Docteur, Elizabeth |
| author2_role | ctb |
| author2_variant | e d ed |
| author_facet | Moïse, Pierre Docteur, Elizabeth |
| author_role | aut |
| author_sort | Moïse, Pierre |
| author_variant | p m pm |
| building | Verbundindex |
| bvnumber | localFWS |
| collection | ZDB-13-SOC |
| ctrlnum | (DE-627-1)06129618X (DE-599)KEP06129618X (FR-PaOEC)302355455158 (EBP)06129618X |
| discipline | Wirtschaftswissenschaften |
| doi_str_mv | 10.1787/302355455158 |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02419cam a22003852 4500</leader><controlfield tag="001">ZDB-13-SOC-06129618X</controlfield><controlfield tag="003">DE-627-1</controlfield><controlfield tag="005">20231204121119.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">210204s2007 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1787/302355455158</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627-1)06129618X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)KEP06129618X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(FR-PaOEC)302355455158</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EBP)06129618X</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">I11</subfield><subfield code="2">jelc</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">I18</subfield><subfield code="2">jelc</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Moïse, Pierre</subfield><subfield code="e">VerfasserIn</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Pharmaceutical Pricing and Reimbursement Policies in Mexico</subfield><subfield code="c">Pierre, Moïse and Elizabeth, Docteur</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Paris</subfield><subfield code="b">OECD Publishing</subfield><subfield code="c">2007</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (66 p.)</subfield><subfield code="c">21 x 29.7cm.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">OECD Health Working Papers</subfield><subfield code="v">no.25</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">This paper examines aspects of the policy environment and market characteristics of Mexico's pharmaceutical sector, and assesses the degree to which Mexico has achieved certain policy goals. This paper questions the effectiveness of the maximum price regulation. It notes that retail prices for pharmaceuticals are relatively high, although proximity to the United States may have some influence. Although not wholly successful in containing overall drug expenditures, the federal government can claim some measure of success for the public sector market. A high reliance on out-of-pocket spending brings into question the sustainability of financing pharmaceuticals in Mexico. It also contributes to greater inequality, although a new health insurance scheme, the Seguro Popular, is addressing the latter with some success as it endeavours to provide coverage for the half of Mexico's population without health insurance. Finally, the paper acknowledges the government.s efforts in improving efficiency of expenditures and quality of care through new bioequivalency requirements for generics. However, an unintended side-effect of the loss of low cost, non-bioequivalent drugs may be higher average prices for pharmaceuticals.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Social Issues/Migration/Health</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Mexico</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Docteur, Elizabeth</subfield><subfield code="e">MitwirkendeR</subfield><subfield code="4">ctb</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="l">FWS01</subfield><subfield code="p">ZDB-13-SOC</subfield><subfield code="q">FWS_PDA_SOC</subfield><subfield code="u">https://doi.org/10.1787/302355455158</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-13-SOC</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-13-SOC</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">BO</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-13-SOC</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-863</subfield></datafield></record></collection> |
| id | ZDB-13-SOC-06129618X |
| illustrated | Not Illustrated |
| indexdate | 2024-11-26T14:55:57Z |
| institution | BVB |
| language | English |
| open_access_boolean | |
| owner | DE-863 DE-BY-FWS |
| owner_facet | DE-863 DE-BY-FWS |
| physical | 1 Online-Ressource (66 p.) 21 x 29.7cm. |
| psigel | ZDB-13-SOC |
| publishDate | 2007 |
| publishDateSearch | 2007 |
| publishDateSort | 2007 |
| publisher | OECD Publishing |
| record_format | marc |
| series2 | OECD Health Working Papers |
| spelling | Moïse, Pierre VerfasserIn aut Pharmaceutical Pricing and Reimbursement Policies in Mexico Pierre, Moïse and Elizabeth, Docteur Paris OECD Publishing 2007 1 Online-Ressource (66 p.) 21 x 29.7cm. Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier OECD Health Working Papers no.25 This paper examines aspects of the policy environment and market characteristics of Mexico's pharmaceutical sector, and assesses the degree to which Mexico has achieved certain policy goals. This paper questions the effectiveness of the maximum price regulation. It notes that retail prices for pharmaceuticals are relatively high, although proximity to the United States may have some influence. Although not wholly successful in containing overall drug expenditures, the federal government can claim some measure of success for the public sector market. A high reliance on out-of-pocket spending brings into question the sustainability of financing pharmaceuticals in Mexico. It also contributes to greater inequality, although a new health insurance scheme, the Seguro Popular, is addressing the latter with some success as it endeavours to provide coverage for the half of Mexico's population without health insurance. Finally, the paper acknowledges the government.s efforts in improving efficiency of expenditures and quality of care through new bioequivalency requirements for generics. However, an unintended side-effect of the loss of low cost, non-bioequivalent drugs may be higher average prices for pharmaceuticals. Social Issues/Migration/Health Mexico Docteur, Elizabeth MitwirkendeR ctb FWS01 ZDB-13-SOC FWS_PDA_SOC https://doi.org/10.1787/302355455158 Volltext |
| spellingShingle | Moïse, Pierre Pharmaceutical Pricing and Reimbursement Policies in Mexico Social Issues/Migration/Health Mexico |
| title | Pharmaceutical Pricing and Reimbursement Policies in Mexico |
| title_auth | Pharmaceutical Pricing and Reimbursement Policies in Mexico |
| title_exact_search | Pharmaceutical Pricing and Reimbursement Policies in Mexico |
| title_full | Pharmaceutical Pricing and Reimbursement Policies in Mexico Pierre, Moïse and Elizabeth, Docteur |
| title_fullStr | Pharmaceutical Pricing and Reimbursement Policies in Mexico Pierre, Moïse and Elizabeth, Docteur |
| title_full_unstemmed | Pharmaceutical Pricing and Reimbursement Policies in Mexico Pierre, Moïse and Elizabeth, Docteur |
| title_short | Pharmaceutical Pricing and Reimbursement Policies in Mexico |
| title_sort | pharmaceutical pricing and reimbursement policies in mexico |
| topic | Social Issues/Migration/Health Mexico |
| topic_facet | Social Issues/Migration/Health Mexico |
| url | https://doi.org/10.1787/302355455158 |
| work_keys_str_mv | AT moisepierre pharmaceuticalpricingandreimbursementpoliciesinmexico AT docteurelizabeth pharmaceuticalpricingandreimbursementpoliciesinmexico |